{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:25:49Z","timestamp":1790623549628,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":197,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1002\/jcph.469","type":"journal-article","created":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T05:39:00Z","timestamp":1423028340000},"page":"708-717","source":"Crossref","is-referenced-by-count":55,"title":["Pharmacokinetic interaction of intravenous fentanyl with ketoconazole"],"prefix":"10.1002","volume":"55","author":[{"given":"Victoria C.","family":"Ziesenitz","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja K.","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina S.","family":"Mahlke","sequence":"additional","affiliation":[{"name":"Institute of Legal and Traffic Medicine; University Hospital Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Skopp","sequence":"additional","affiliation":[{"name":"Institute of Legal and Traffic Medicine; University Hospital Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology; University Hospital Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,16]]},"reference":[{"issue":"3 Suppl","key":"10.1002\/jcph.469-BIB0001|jcph469-cit-0001","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/0885-3924(92)90047-L","article-title":"The history and development of the fentanyl series","volume":"7","author":"Stanley","year":"1992","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"10.1002\/jcph.469-BIB0002|jcph469-cit-0002","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2165\/00003088-198308050-00004","article-title":"Clinical pharmacokinetics of fentanyl and its newer derivatives","volume":"8","author":"Mather","year":"1983","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1002\/jcph.469-BIB0003|jcph469-cit-0003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dot.2012.48.2.1745275","article-title":"New formulations of fentanyl for acute pain management","volume":"48","author":"Paech","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"10.1002\/jcph.469-BIB0004|jcph469-cit-0004","unstructured":"2013 https:\/\/www.incb.org\/incb\/en\/narcotic-drugs\/Technical_Reports\/2013\/narcotic-drugs-technical-report-2013"},{"issue":"3","key":"10.1002\/jcph.469-BIB0005|jcph469-cit-0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"10.1002\/jcph.469-BIB0006|jcph469-cit-0006","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0090-9556(25)07486-0","article-title":"Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4","volume":"24","author":"Feierman","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1002\/jcph.469-BIB0007|jcph469-cit-0007","first-page":"167","article-title":"Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation","volume":"82","author":"Tateishi","year":"1996","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1002\/jcph.469-BIB0008|jcph469-cit-0008","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2133\/dmpk.DMPK-11-RG-134","article-title":"Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system","volume":"27","author":"Takashina","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1002\/jcph.469-BIB0009|jcph469-cit-0009","first-page":"1072","article-title":"Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3 A4: implications for interindividual variability in disposition, efficacy, and drug interactions","volume":"25","author":"Labroo","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1002\/jcph.469-BIB0010|jcph469-cit-0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00228-006-0120-4","article-title":"Possible fluconazole-fentanyl interaction-a case report","volume":"62","author":"Hallberg","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1002\/jcph.469-BIB0011|jcph469-cit-0011","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jpainsymman.2009.02.230","article-title":"Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD","volume":"37","author":"Horton","year":"2009","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10.1002\/jcph.469-BIB0012|jcph469-cit-0012","doi-asserted-by":"crossref","first-page":"648 e","DOI":"10.1016\/j.genhosppsych.2010.08.003","article-title":"Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction","volume":"32","author":"Levin","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"10.1002\/jcph.469-BIB0013|jcph469-cit-0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0885-3924(02)00477-3","article-title":"Itraconazole-fentanyl interaction in a cancer patient","volume":"24","author":"Mercadante","year":"2002","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1002\/jcph.469-BIB0014|jcph469-cit-0014","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/00000542-200304000-00011","article-title":"Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil","volume":"98","author":"Ibrahim","year":"2003","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1002\/jcph.469-BIB0015|jcph469-cit-0015","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00000542-199909000-00020","article-title":"Ritonavir's role in reducing fentanyl clearance and prolonging its half-life","volume":"91","author":"Olkkola","year":"1999","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1002\/jcph.469-BIB0016|jcph469-cit-0016","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/bja\/81.4.598","article-title":"The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl","volume":"81","author":"Palkama","year":"1998","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1002\/jcph.469-BIB0017|jcph469-cit-0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00228-007-0398-x","article-title":"Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl","volume":"64","author":"Saari","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1002\/jcph.469-BIB0018|jcph469-cit-0018","first-page":"936","article-title":"Identification of cytochrome P450 3A1\/2 as the major P450 isoform responsible for the metabolism of fentanyl by rat liver microsomes","volume":"82","author":"Feierman","year":"1996","journal-title":"Anesth Analg"},{"issue":"6","key":"10.1002\/jcph.469-BIB0019|jcph469-cit-0019","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bja\/79.6.740","article-title":"I.v. fentanyl decreases the clearance of midazolam","volume":"79","author":"Hase","year":"1997","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1002\/jcph.469-BIB0020|jcph469-cit-0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/bja\/82.6.900","article-title":"Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro","volume":"82","author":"Oda","year":"1999","journal-title":"Br J Anaesth"},{"issue":"5","key":"10.1002\/jcph.469-BIB0021|jcph469-cit-0021","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00414-014-1040-y","article-title":"Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS\/MS)","volume":"128","author":"Mahlke","year":"2014","journal-title":"Int J Legal Med"},{"issue":"24","key":"10.1002\/jcph.469-BIB0022|jcph469-cit-0022","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1002\/rcm.1719","article-title":"A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography\/electrospray mass spectrometry","volume":"18","author":"Quintela","year":"2004","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"5","key":"10.1002\/jcph.469-BIB0023|jcph469-cit-0023","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1002\/jcph.469-BIB0024|jcph469-cit-0024","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/0091270007299756","article-title":"Fentanyl clearance and volume of distribution are increased in patients with major burns","volume":"47","author":"Han","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jcph.469-BIB0025|jcph469-cit-0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/clpt.1980.138","article-title":"Intravenous fentanyl kinetics","volume":"28","author":"McClain","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jcph.469-BIB0026|jcph469-cit-0026","unstructured":"2011 http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm#classInhibit"},{"issue":"6","key":"10.1002\/jcph.469-BIB0027|jcph469-cit-0027","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1002\/jcph.469-BIB0028|jcph469-cit-0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06653-0","article-title":"Clearance approaches in pharmacology","volume":"39","author":"Wilkinson","year":"1987","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1002\/jcph.469-BIB0029|jcph469-cit-0029","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00228-012-1388-1","article-title":"Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity","volume":"69","author":"Fuchs","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1002\/jcph.469-BIB0030|jcph469-cit-0030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/clpt.2013.27","article-title":"A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions","volume":"93","author":"Halama","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jcph.469-BIB0031|jcph469-cit-0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"issue":"20","key":"10.1002\/jcph.469-BIB0032|jcph469-cit-0032","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1158\/1078-0432.CCR-05-0520","article-title":"Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients","volume":"15","author":"Lepper","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1002\/jcph.469-BIB0033|jcph469-cit-0033","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","article-title":"General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs","volume":"46","author":"Ohno","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1002\/jcph.469-BIB0034|jcph469-cit-0034","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00228-010-0878-2","article-title":"Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam","volume":"66","author":"Katzenmaier","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1002\/jcph.469-BIB0035|jcph469-cit-0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1067\/mcp.2002.129068","article-title":"Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping","volume":"72","author":"Lee","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1002\/jcph.469-BIB0036|jcph469-cit-0036","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","article-title":"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole","volume":"66","author":"Tsunoda","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1002\/jcph.469-BIB0037|jcph469-cit-0037","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0091270008331133","article-title":"Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm","volume":"49","author":"Stoch","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jcph.469-BIB0038|jcph469-cit-0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00540-003-0214-4","article-title":"Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl","volume":"18","author":"Takahashi","year":"2004","journal-title":"J Anesth"},{"key":"10.1002\/jcph.469-BIB0039|jcph469-cit-0039","unstructured":"2014 http:\/\/www.medicines.org.uk\/emc\/medicine\/17086\/SPC\/Durogesic + DTrans + 12 + 25 + 50 + 75 + 100 + mcg + hr + Transdermal + Patch\/ http:\/\/www.medicines.org.uk\/emc\/medicine\/17086\/SPC\/Durogesic + DTrans + 12 + 25 + 50 + 75 + 100 + mcg + hr + Transdermal + Patch\/"},{"issue":"6","key":"10.1002\/jcph.469-BIB0040|jcph469-cit-0040","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/bja\/60.6.608","article-title":"Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery","volume":"60","author":"Holley","year":"1988","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1002\/jcph.469-BIB0041|jcph469-cit-0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000542-199301000-00007","article-title":"Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics","volume":"78","author":"Portenoy","year":"1993","journal-title":"Anesthesiology"},{"key":"10.1002\/jcph.469-BIB0042|jcph469-cit-0042","article-title":"Expression of CYP3A in chronic ethanol-fed mice is mediated by endogenous pregnane X receptor ligands formed by enhanced cholesterol metabolism","author":"Je","year":"2014","journal-title":"Arch Toxicol"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.469","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.469\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T05:18:11Z","timestamp":1747545491000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,16]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.469","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2,16]]}}}